Northern Trust Corp Buys Shares of 21,627 NewAmsterdam Pharma (NASDAQ:NAMS)

Northern Trust Corp purchased a new position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 21,627 shares of the company's stock, valued at approximately $556,000.

Other institutional investors have also modified their holdings of the company. National Bank of Canada FI acquired a new position in shares of NewAmsterdam Pharma in the fourth quarter worth about $51,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in NewAmsterdam Pharma during the fourth quarter valued at approximately $80,000. KLP Kapitalforvaltning AS acquired a new stake in NewAmsterdam Pharma during the fourth quarter valued at approximately $154,000. The Manufacturers Life Insurance Company acquired a new stake in NewAmsterdam Pharma during the fourth quarter valued at approximately $221,000. Finally, Keybank National Association OH acquired a new stake in NewAmsterdam Pharma during the fourth quarter valued at approximately $257,000. Institutional investors and hedge funds own 89.89% of the company's stock.

NewAmsterdam Pharma Price Performance

Shares of NAMS traded up $0.82 during trading hours on Monday, hitting $18.93. 759,365 shares of the company were exchanged, compared to its average volume of 646,542. The company has a market capitalization of $2.13 billion, a PE ratio of -10.07 and a beta of 0.01. The firm has a fifty day simple moving average of $17.96 and a 200-day simple moving average of $20.97. NewAmsterdam Pharma has a one year low of $14.06 and a one year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.04). The firm had revenue of $2.98 million during the quarter, compared to analyst estimates of $1.46 million. Sell-side analysts expect that NewAmsterdam Pharma will post -1.75 EPS for the current year.

Insider Transactions at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 150,000 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the completion of the sale, the chief accounting officer now directly owns 15,000 shares in the company, valued at approximately $305,550. This trade represents a 90.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director James N. Topper acquired 4,005 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The shares were purchased at an average price of $21.02 per share, with a total value of $84,185.10. Following the completion of the acquisition, the director now owns 3,012,434 shares of the company's stock, valued at $63,321,362.68. This represents a 0.13% increase in their position. The disclosure for this purchase can be found here. 20.84% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

NAMS has been the topic of a number of research reports. UBS Group set a $41.00 price target on NewAmsterdam Pharma in a research report on Monday, March 3rd. Wall Street Zen raised NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research note on Friday. Scotiabank boosted their price objective on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Thursday, February 27th. Finally, Needham & Company LLC dropped their price objective on NewAmsterdam Pharma from $42.00 to $40.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $43.00.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.